Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06688188
Recruiting Early Phase 1

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

NCT06688188 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Early Phase 1
Started
2024-11-01
Last updated
2024-11-14

Condition(s) studied

Malignant Neoplasm

Investigational drug(s) / intervention(s)

68Ga-JH12

68Ga-JH12: The dose will be 148-222 MBq given intravenously.

Study summary

68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Various solid tumors with available histopathological findings * Signed informed consent Exclusion Criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency

Primary outcome measure(s)

  • safety and tolerability — up to 1 week
    Hematologic status, liver function, renal function and General vital signs were recorded before and 1 week after administration of radiopharmaceutical. Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0.

Trial sites (1)

FacilityCityRegionStatus
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University Fuzhou Fujian Recruiting

More First Affiliated Hospital of Fujian Medical University trials in China

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer Recruiting
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes Recruiting
68Ga-FAPI PET/CT in Patients With Various Types of Cancer Recruiting
A Registered Cohort Study on Amyotrophic Lateral Sclerosis Recruiting
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI Recruiting

Other trials for the same condition

68Ga-FAPI PET/CT in Malignant Tumors Recruiting
NV-001 in the Treatment of Advanced Solid Tumors Recruiting
68Ga-NI-FAPI PET/CT: First-in-human Study Recruiting
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06688188 on ClinicalTrials.gov ↗ ← All trials in China